Alexion Pharmaceuticals, Inc. (ALXN) on Tuesday announced restructuring efforts that will cut the pharmaceutical company's global workforce by 20% as it looks to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019.

Shares of the company were falling over 1% in Tuesday morning trading. 

"These changes were necessary to enable the Company to deliver sustainable long-term performance to support our ability to continue to develop and deliver life-changing therapies for patients," Alexion CEO Ludwig Hantson said.

The reductions will result in cost savings that will allow the New Haven, CT.-based pharma company to drive growth opportunities, "optimize" its capabilities, and enable it to reach its financial goals of increasing GAAP operating margin to 37% and non-GAAP operating margin to 50% in 2019, the company said.

The resulting financial flexibility will also allow Alexion to reinvest $100 million per year into research and development. 

More of What's Trending on TheStreet:

More from Stocks

Global Stocks Mixed as China GDP Slows, Brexit Uncertainty Hangs Over Europe

Global Stocks Mixed as China GDP Slows, Brexit Uncertainty Hangs Over Europe

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Why Bankrate's CFA Expects Two More Rate Hikes in 2019

Why Bankrate's CFA Expects Two More Rate Hikes in 2019

Norwegian Cruise Lines Could Be Docking With a Dividend in 2019

Norwegian Cruise Lines Could Be Docking With a Dividend in 2019

Why Sears is One of Jim Cramer's 'Finest Hours'

Why Sears is One of Jim Cramer's 'Finest Hours'